Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Parkinson's disease (PD) is the second most common neurodegenerative disorder that
affects approximately 1% of people over the age of 60 years. Accurate diagnosis and …

Objective Real‐life observational report of clinical efficacy of bilateral subthalamic
stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on …

Motor complications in Parkinson's disease (PD) are associated with long‐term oral
levodopa treatment and linked to pulsatile dopaminergic stimulation. l‐dopa‐carbidopa …

Patients in fluctuating stages of Parkinson's disease (PD) require device-aided treatments.
Continuous infusion of levodopa–carbidopa intestinal gel (LCIG) is a well-proven option in …

The gut brain axis (GBA), a bidirectional communication pathway has often been linked to
health and disease, and gut microbiota (GM), a key component of this pathway shown to be …

Background Levodopa–carbidopa intestinal gel (LCIG) is available in several countries for
the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor …

Background Continuous administration of levodopa‐carbidopa intestinal gel (carbidopa‐
levodopa enteral suspension) through a percutaneous endoscopic gastrojejunostomy is a …

Background: Levodopa‐carbidopa intestinal gel (designated as carbidopa‐levodopa enteral
suspension in the United States) provides stable plasma levodopa concentrations and …

Several different strategies are effective for medical treatment of motor problems in
Parkinson's disease (PD). Many guidelines and evidence‐based reviews are available, but …